A novel multiplexed biomarker panel reveals key molecular pathways in progressive multiple sclerosis - PubMed
3 hours ago
- #multiplex immunoassay
- #PIRMA
- #neuroinflammation
- The study identifies distinct proteomic signatures in cerebrospinal fluid of patients with relapsing-remitting and inactive progressive multiple sclerosis, compared to controls, with no significant differences in plasma.
- Low baseline KIT ligand in cerebrospinal fluid predicts conversion to secondary progressive multiple sclerosis and progression independent of relapse and MRI activity, highlighting its potential as a prognostic biomarker.
- Elevated plasma levels of interleukin-1 beta and interleukin-36 gamma in relapsing-remitting patients are associated with future progression to secondary progressive disease, with a two-protein model showing high diagnostic accuracy.